Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Scher

Showing results (341-350 of 692) with videos related to

Pageof 70
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 1995
Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasmsH I Scher, A Sarkis, V Reuter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1997
Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinomaJ A McCaffrey, S Hilton, M Mazumdar, et al.
Clinical Genitourinary Cancer|February 15, 2020
A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate CancerDeaglan J McHugh, Jay Chudow, Mia DeNunzio, et al.
The Lancet. Oncology|August 9, 2014
Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trialKarim Fizazi, Howard I Scher, Kurt Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2000
Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancerM J Zelefsky, W K Kelly, H I Scher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1994
Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumorsR J Motzer, D F Bajorin, L H Schwartz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2016
The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer PopulationGlenn Heller, Karim Fizazi, Robert McCormack, et al.
JAMA Neurology|September 14, 2019
Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple SclerosisKjetil Bjornevik, Kassandra L Munger, Marianna Cortese, et al.
Clinical Genitourinary Cancer|March 13, 2022
Automated Bone Scan Index to Optimize Prostate Cancer Working Group Radiographic Progression Criteria for Men With Metastatic Castration-Resistant Prostate CancerAseem Anand, Glenn Heller, Joseph Fox, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2006
Rapid androgen cycling as treatment for patients with prostate cancerDavid Feltquate, Luke Nordquist, Caitlin Eicher, et al.
Pageof 70

Showing results (341-350 of 692) with videos related to

Sort By:
Pageof 70
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 1995
Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasmsH I Scher, A Sarkis, V Reuter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1997
Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinomaJ A McCaffrey, S Hilton, M Mazumdar, et al.
Clinical Genitourinary Cancer|February 15, 2020
A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate CancerDeaglan J McHugh, Jay Chudow, Mia DeNunzio, et al.
The Lancet. Oncology|August 9, 2014
Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trialKarim Fizazi, Howard I Scher, Kurt Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2000
Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancerM J Zelefsky, W K Kelly, H I Scher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1994
Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumorsR J Motzer, D F Bajorin, L H Schwartz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2016
The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer PopulationGlenn Heller, Karim Fizazi, Robert McCormack, et al.
JAMA Neurology|September 14, 2019
Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple SclerosisKjetil Bjornevik, Kassandra L Munger, Marianna Cortese, et al.
Clinical Genitourinary Cancer|March 13, 2022
Automated Bone Scan Index to Optimize Prostate Cancer Working Group Radiographic Progression Criteria for Men With Metastatic Castration-Resistant Prostate CancerAseem Anand, Glenn Heller, Joseph Fox, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2006
Rapid androgen cycling as treatment for patients with prostate cancerDavid Feltquate, Luke Nordquist, Caitlin Eicher, et al.
Pageof 70